Middle East Gene therapy is a high-tech Company located in Iran established in June 2019 and focused on Gene therapy. Introducing novel gene therapy method, we want to develop a new generation of CAR T cells and other GTMPs that are in the international market. We want to catch the market in Middle East Countries by current GTMPs technology transfer in each region. Our core Business in Middle East Gene therapy Co. is development of a Virus-Free hardware technology called INGENEES, which is an acronym stands for “Injection Genetic System” and its commercialization in Canada and North America. INGENEES is a novel Gene Editing technology whose prototype was launched on 2018 in Iran.
Also the Virus-Free CAR-T cell therapy technology development and Commercialization is our main goal. Special diseases and clinical problems like Acute Lymphoblastic Leukemia, Lymphoma, Solid tumors, Thalassemia, SCID and a few of critical health problems, are our targets to solve them.
In our Strategic plan, we want to have a Co-operative and collaborative International partnership. Virus-Free Car-T cell is a novel and advanced technology in conjunction with INGENEES is in co-development process in Hong Kong and Iran.
In addition, Virus-based CAR-T cell therapy Tech transfer from technology owner’s companies including China is in progress and will be started in a few months. Our Partnership Approaches is based on Joint Venture in Iran or targeted countries, venture Capital investment in High Tech solutions for technology development and commercialization, franchising and or Technology Transfer from or to Iran, clinical Setting and establishment in Iran and other countries especially in MENA region including Qatar, UAE and Oman.